drugset
drugset / Trial / NCT06547216

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT06547216 ↗

Phase 2 Active not recruiting 84 enrolled Avidity Biosciences, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Timeline

Start
2024-07-25
Primary completion
2030-04
Completion
2030-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AOC 1020 Unknown 2 mg/kg Intravenous

Indications

facioscapulohumeral muscular dystrophy 1 facioscapulohumeral muscular dystrophy 2 fibromuscular dysplasia frontometaphyseal dysplasia 2 hypogonadotropic hypogonadism 24 without anosmia